Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19

Detalles Bibliográficos
Autores principales: Dimosiari, Athina, Patoulias, Dimitrios, Pantazopoulos, Ioannis, Zakynthinos, Epaminondas, Makris, Demosthenes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666376/
https://www.ncbi.nlm.nih.gov/pubmed/36462963
http://dx.doi.org/10.1016/j.ejim.2022.11.014
_version_ 1784831491774087168
author Dimosiari, Athina
Patoulias, Dimitrios
Pantazopoulos, Ioannis
Zakynthinos, Epaminondas
Makris, Demosthenes
author_facet Dimosiari, Athina
Patoulias, Dimitrios
Pantazopoulos, Ioannis
Zakynthinos, Epaminondas
Makris, Demosthenes
author_sort Dimosiari, Athina
collection PubMed
description
format Online
Article
Text
id pubmed-9666376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Federation of Internal Medicine. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-96663762022-11-16 Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19 Dimosiari, Athina Patoulias, Dimitrios Pantazopoulos, Ioannis Zakynthinos, Epaminondas Makris, Demosthenes Eur J Intern Med Letter to the Editor European Federation of Internal Medicine. Published by Elsevier B.V. 2023-03 2022-11-16 /pmc/articles/PMC9666376/ /pubmed/36462963 http://dx.doi.org/10.1016/j.ejim.2022.11.014 Text en © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Dimosiari, Athina
Patoulias, Dimitrios
Pantazopoulos, Ioannis
Zakynthinos, Epaminondas
Makris, Demosthenes
Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title_full Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title_fullStr Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title_full_unstemmed Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title_short Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
title_sort safety and efficacy of interleukin-1 antagonists in hospitalized patients with covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666376/
https://www.ncbi.nlm.nih.gov/pubmed/36462963
http://dx.doi.org/10.1016/j.ejim.2022.11.014
work_keys_str_mv AT dimosiariathina safetyandefficacyofinterleukin1antagonistsinhospitalizedpatientswithcovid19
AT patouliasdimitrios safetyandefficacyofinterleukin1antagonistsinhospitalizedpatientswithcovid19
AT pantazopoulosioannis safetyandefficacyofinterleukin1antagonistsinhospitalizedpatientswithcovid19
AT zakynthinosepaminondas safetyandefficacyofinterleukin1antagonistsinhospitalizedpatientswithcovid19
AT makrisdemosthenes safetyandefficacyofinterleukin1antagonistsinhospitalizedpatientswithcovid19

Ejemplares similares